62 related articles for article (PubMed ID: 21195878)
21. Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy.
Tai CJ; Lo HY; Hsu CH; Tai CJ; Liu WM
Gynecol Oncol; 2006 Apr; 101(1):184-5. PubMed ID: 16413601
[No Abstract] [Full Text] [Related]
22. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.
Persson MI; Gedda L; Jensen HJ; Lundqvist H; Malmström PU; Tolmachev V
Oncol Rep; 2006 Mar; 15(3):673-80. PubMed ID: 16465429
[TBL] [Abstract][Full Text] [Related]
23. Optimized digital counting colonies of clonogenic assays using ImageJ software and customized macros: comparison with manual counting.
Cai Z; Chattopadhyay N; Liu WJ; Chan C; Pignol JP; Reilly RM
Int J Radiat Biol; 2011 Nov; 87(11):1135-46. PubMed ID: 21913819
[TBL] [Abstract][Full Text] [Related]
24. Differences in radiosensitivity between three HER2 overexpressing cell lines.
Steffen AC; Göstring L; Tolmachev V; Palm S; Stenerlöw B; Carlsson J
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1179-91. PubMed ID: 18193218
[TBL] [Abstract][Full Text] [Related]
25. Visualization of HER2-specific breast cancer intratumoral heterogeneity using
Sasada S; Kurihara H; Kinoshita T; Yoshida M; Honda N; Shimoi T; Shimomura A; Yonemori K; Shimizu C; Hamada A; Kanayama Y; Watanabe Y; Fujiwara Y; Tamura K
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2146-2147. PubMed ID: 28770275
[No Abstract] [Full Text] [Related]
26. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.
Abbas N; Heyerdahl H; Bruland OS; Borrebæk J; Nesland J; Dahle J
EJNMMI Res; 2011 Aug; 1(1):18. PubMed ID: 22214432
[TBL] [Abstract][Full Text] [Related]
27. Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability.
Larsen RH; Borrebaek J; Dahle J; Melhus KB; Krogh C; Valan MH; Bruland OS
Cancer Biother Radiopharm; 2007 Jun; 22(3):431-7. PubMed ID: 17651051
[TBL] [Abstract][Full Text] [Related]
28. Why should the clonogenic cell assay be prognostically important in ovarian cancer?
Cannistra SA
J Clin Oncol; 1991 Mar; 9(3):368-70. PubMed ID: 1999705
[No Abstract] [Full Text] [Related]
29. Antibody-drug conjugates: can the payload improve activity in HER2 expressing cancers?
Shah MA
Lancet Oncol; 2017 Nov; 18(11):1433-1434. PubMed ID: 29037986
[No Abstract] [Full Text] [Related]
30. A new agent in the family of antibody-drug conjugates.
Pivot X; Petit T
Lancet Oncol; 2019 Aug; 20(8):1043-1044. PubMed ID: 31257178
[No Abstract] [Full Text] [Related]
31. Irradiation and monocyte function in patients with breast cancer.
Taylor SA; Gordon MY; Currie GA; Shepherd VB
Int J Radiat Oncol Biol Phys; 1979; 5(11-12):2063-7. PubMed ID: 544587
[No Abstract] [Full Text] [Related]
32. QnAs with H. Michael Shepard and Dennis J. Slamon.
Davis TH
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):796-798. PubMed ID: 31888982
[No Abstract] [Full Text] [Related]
33. Alpha decay of 231U to levels in 227Th.
Liang CF; Sheline RK; Paris P; Hussonois M; Ledu JF; Isabelle DB
Phys Rev C Nucl Phys; 1994 Apr; 49(4):2230-2232. PubMed ID: 9969455
[No Abstract] [Full Text] [Related]
34. Level structure and reflection asymmetry in 227Th.
Liang CF; Paris P; Sheline RK; Nosek D; Kvasil J
Phys Rev C Nucl Phys; 1995 Mar; 51(3):1199-1210. PubMed ID: 9970169
[No Abstract] [Full Text] [Related]
35. Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
Böhnke N; Indrevoll B; Hammer S; Papple A; Kristian A; Briem H; Celik A; Mumberg D; Cuthbertson A; Zitzmann-Kolbe S
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):669-680. PubMed ID: 37882848
[TBL] [Abstract][Full Text] [Related]
36. Targeted thorium-227 conjugates as treatment options in oncology.
Karlsson J; Schatz CA; Wengner AM; Hammer S; Scholz A; Cuthbertson A; Wagner V; Hennekes H; Jardine V; Hagemann UB
Front Med (Lausanne); 2022; 9():1071086. PubMed ID: 36726355
[TBL] [Abstract][Full Text] [Related]
37. Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
Pallares RM; Abergel RJ
Front Med (Lausanne); 2022; 9():1020188. PubMed ID: 36619636
[TBL] [Abstract][Full Text] [Related]
38. Design and characterization of a time-domain optical tomography platform for mesoscopic lifetime imaging.
Gao S; Li M; Smith JT; Intes X
Biomed Opt Express; 2022 Sep; 13(9):4637-4651. PubMed ID: 36187247
[TBL] [Abstract][Full Text] [Related]
39. Fusion of apoptosis-related protein Cytochrome c with anti-HER-2 single-chain antibody targets the suppression of HER-2+ breast cancer.
Lu D; Guo Y; Hu Y; Wang M; Li C; Gangrade A; Chen J; Zheng Z; Guo J
J Cell Mol Med; 2021 Nov; 25(22):10638-10649. PubMed ID: 34697906
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals in the Context of SARS-CoV-2.
Pallares RM; Abergel RJ
ACS Pharmacol Transl Sci; 2021 Feb; 4(1):1-7. PubMed ID: 33615159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
